These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy. King CR; Presti JC; Brooks JD; Gill H; Spiotto MT Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1472-7. PubMed ID: 17935902 [TBL] [Abstract][Full Text] [Related]
5. Serum prostate-specific antigen elevation in the post-radical prostatectomy patient. Malkowicz SB Urol Clin North Am; 1996 Nov; 23(4):665-75. PubMed ID: 8948419 [TBL] [Abstract][Full Text] [Related]
6. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy? Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426 [TBL] [Abstract][Full Text] [Related]
7. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Ost P; De Troyer B; Fonteyne V; Oosterlinck W; De Meerleer G Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1316-22. PubMed ID: 20675081 [TBL] [Abstract][Full Text] [Related]
8. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? King CR; Presti JC; Gill H; Brooks J; Hancock SL Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):341-7. PubMed ID: 15145146 [TBL] [Abstract][Full Text] [Related]
9. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. Katz MS; Zelefsky MJ; Venkatraman ES; Fuks Z; Hummer A; Leibel SA J Clin Oncol; 2003 Feb; 21(3):483-9. PubMed ID: 12560439 [TBL] [Abstract][Full Text] [Related]
10. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial. Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850 [TBL] [Abstract][Full Text] [Related]
11. Salvage radiotherapy in patients with persisting/rising PSA after radical prostatectomy for prostate cancer. Bottke D; de Reijke TM; Bartkowiak D; Wiegel T Eur J Cancer; 2009 Sep; 45 Suppl 1():148-57. PubMed ID: 19775613 [No Abstract] [Full Text] [Related]
12. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience. Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750 [TBL] [Abstract][Full Text] [Related]
13. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Cheung R; Kamat AM; de Crevoisier R; Allen PK; Lee AK; Tucker SL; Pisters L; Babaian RJ; Kuban D Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):134-40. PubMed ID: 16111581 [TBL] [Abstract][Full Text] [Related]
14. [Salvage radiotherapy in rising PSA after radical prostatectomy]. Carrie C; Pommier P Cancer Radiother; 2007 Nov; 11(6-7):370-2. PubMed ID: 17869564 [TBL] [Abstract][Full Text] [Related]
15. Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy. Rigaud J; Tiguert R; Decobert M; Hovington H; Latulippe E; Laverdiere J; Larue H; Lacombe L; Fradet Y Prostate; 2004 Feb; 58(3):269-76. PubMed ID: 14743466 [TBL] [Abstract][Full Text] [Related]
16. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery). Parker C; Clarke N; Logue J; Payne H; Catton C; Kynaston H; Murphy C; Morgan R; Morash C; Parulekar W; Parmar M; Savage C; Stansfeld J; Sydes M; Clin Oncol (R Coll Radiol); 2007 Apr; 19(3):167-71. PubMed ID: 17359901 [No Abstract] [Full Text] [Related]
17. PSA response to thalidomide in patients with advanced prostate cancer. Leibowitz R; Tucker SJ Oncology (Williston Park); 2002 Sep; 16(9):1146, 1148. PubMed ID: 12380944 [No Abstract] [Full Text] [Related]
18. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. King CR; Spiotto MT Int J Radiat Oncol Biol Phys; 2008 May; 71(1):23-7. PubMed ID: 18207668 [TBL] [Abstract][Full Text] [Related]
19. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy for prostate cancer patients at high risk of recurrence following radical prostatectomy. Andriole GL Eur Urol; 1997; 32 Suppl 3():65-9. PubMed ID: 9267788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]